CUORIPS Inc. Announces Acceptance of Abstract on Groundbreaking Cardiac Regenerative Therapy at AHA's BCVS 2026

CUORIPS Inc. is pleased to announce that its abstract, entitled “Minimally Invasive Transplantation of Regenerative Cardiac Organoids Improves Regional Myocardial Function in Ischemic Cardiomyopathy,” has been accepted for presentation at the American Heart Association (AHA) Basic Cardiovascular Sciences Scientific Sessions 2026 (BCVS 2026).

BCVS is a premier international scientific conference focused on basic and translational cardiovascular research, bringing together leading researchers and clinicians from around the world. BCVS 2026 will be held in Boston, Massachusetts, USA, from July 13–16, 2026.

The presentation will highlight our pioneering research and the therapeutic potential of a minimally invasive regenerative approach for the treatment of ischemic cardiomyopathy. 

This prestigious acceptance underscores the global significance and innovative nature of CUORIPS' advanced tissue-engineering platform.

Additional details regarding the presentation format (oral or poster) and session schedule will be announced as they are finalized by the conference organizers.